Supernus Pharmaceuticals, Inc. — 2012 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2012. The filing also reports unaudited fourth-quarter results. Amounts are in U.S. dollars.
Business context
Supernus is a CNS-focused specialty pharmaceutical company moving from drug development toward commercialization. It had no product-sales revenue in 2012. FDA approved Oxtellar XR in October 2012; the company launched it on February 4, 2013. Trokendi XR had tentative FDA approval, with final approval and a planned third-quarter 2013 launch subject to FDA action and the expiration of pediatric exclusivity on June 22, 2013. The company’s other principal candidates were SPN-810 and SPN-812 for ADHD-related indications.
Financial performance and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Revenue | $1.480 million | $0.803 million |
| Research and development expense | $23.517 million | $30.627 million |
| Selling, general and administrative expense | $20.132 million | $7.928 million |
| Total operating expenses | $43.649 million | $38.555 million |
| Operating loss | $42.169 million | $37.752 million |
| Net income (loss) | $(46.284) million | $53.815 million |
| Basic and diluted EPS | $(2.72) | $31.39 |
| Net cash used in operating activities | $47.199 million | $36.185 million |
FY 2012 revenue consisted of development and milestone revenues, including $1.1 million in milestone payments and recognition of previously deferred license payments; it did not include product sales. Product gross margin therefore was not yet meaningful. R&D expense declined 23%, principally with lower Oxtellar XR and Trokendi XR trial costs, while SG&A rose 154% as the company prepared for launches.
Fourth-quarter 2012 revenue was $1.090 million, total costs and expenses were $13.834 million, operating and net loss were each $13.512 million, and loss per share was $0.51. In fourth-quarter 2011, reported net income was $81.975 million, including a $76.394 million discontinued-operations gain; continuing operations also benefited from a $16.2 million tax benefit. These one-time items make the year-over-year earnings comparison unrepresentative of underlying operating performance.
At year-end, cash and cash equivalents were $40.302 million and marketable securities were $48.206 million, totaling $88.508 million unrestricted; restricted marketable securities were $0.279 million. Working capital was $68.758 million and total assets were $93.989 million. The company reported $57.570 million of stockholders’ equity and an accumulated deficit of $86.255 million.
Secured notes had $23.225 million principal outstanding at year-end, carried a fixed 11% interest rate, and were due in 2014 and 2015; the balance-sheet carrying amount was $22.897 million. Contractual obligations totaled $35.377 million, including scheduled debt principal and interest, leases, and purchase obligations. The debt is secured by substantially all assets other than intellectual property and includes restrictive covenants.
Material changes and notable items
- Net loss in 2012 followed 2011 net income, which was driven principally by the sale of TCD Royalty Sub and related discontinued-operations gain. The 2011 result also included a $16.245 million income tax benefit.
- The company raised net proceeds of $47.6 million in its May 2012 IPO and $46.6 million in its November 2012 follow-on offering. Financing cash flow was $87.916 million in 2012.
- Operating cash use increased to $47.199 million from $36.185 million in 2011. The company also shifted funds into marketable securities; year-end cash alone was $40.302 million.
- Interest expense increased to $3.575 million from $1.866 million, reflecting the secured borrowing and related costs. A change in the fair value of warrant liabilities also affected other expense.
Outlook, risks and contingencies
Management estimated that available cash and the 2012 offering proceeds would fund operations as then planned into the fourth quarter of 2013. It stated that additional capital would be needed to fund planned operations beyond that point; financing availability and terms were uncertain. The independent auditor’s report included a going-concern explanatory paragraph, citing recurring operating losses, negative operating cash flows and the need for additional capital. Management warned that without financing it could need to revise commercial plans, reduce operations, or delay, narrow or eliminate development programs.
- Management expected continued significant operating losses and increased commercial spending. It planned to expand the sales force beyond approximately 75 representatives to support Trokendi XR, if finally approved. No quantified revenue or earnings guidance was provided.
- Trokendi XR’s final approval and launch timing were uncertain. The filing notes a prior FDA refusal to file the application over chemistry and manufacturing issues and tentative approval pending pediatric safety labeling/exclusivity matters.
- Oxtellar XR and Trokendi XR commercialization depends on physician and payer acceptance, pricing and reimbursement, manufacturing scale-up, and effective sales execution. The company relied on single suppliers and manufacturers for key materials and commercial products.
- SPN-810’s Phase IIb topline results were encouraging in certain dose and weight subgroups, but efficacy was not statistically significant across all measures and the high dose did not show significant efficacy. The full dataset and Phase III design remained under review and required FDA discussion. SPN-812 had completed Phase IIa; an extended-release formulation was planned for future Phase IIb study.
- United Therapeutics received an FDA complete response letter for oral treprostinil in October 2012. Supernus did not expect royalties on that formulation unless and until approval and commercial launch occurred.
- Other material risks include competition from generic and branded drugs, potential adverse safety findings, patent challenges, reimbursement and healthcare-pricing pressure, and the possibility of further equity issuance and dilution. Management reported disclosure controls and internal control over financial reporting as effective; the auditor did not provide an internal-control audit opinion.
Important facts for investors to verify
- Subsequent FDA decisions and actual commercial uptake, net pricing, reimbursement, and sales deductions for Oxtellar XR and Trokendi XR.
- Cash burn, remaining liquidity, financing plans and terms, and whether the company’s stated runway assumptions were achieved.
- Debt repayment schedule, covenant compliance, interest burden, and any impact of secured-credit terms on financing flexibility.
- Full SPN-810 Phase IIb analyses and the FDA-agreed development plan, alongside SPN-812 trial timing and costs.
- Manufacturing capacity and supplier continuity, competitive extended-release products, and any material changes in patent or litigation exposure.